We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

FDA Clarifies and Expands Eligibility for RMAT Designation for Gene Therapies

David Horowitz

David Horowitz,

Washington, D.C.

Michael N. Druckman

Michael N. Druckman,

Washington, D.C.

David M. Fox

David M. Fox,

Washington, D.C.

Susan S. Lee

Susan S. Lee,

Washington, D.C.

22 November 2017

On November 16, in the context of announcing a comprehensive regenerative medicine policy framework (discussed here), FDA released a draft guidance document that describes the expedited programs available for the development and review of certain regenerative medicine therapies.  Importantly, the draft guidance clarifies certain aspects of the Regenerative Medicine Advanced Therapy (RMAT) designation established by the 21st Century Cures Act.  In particular, the draft guidance expressly includes “gene therapies, including genetically modified cells, that lead to a durable modification of cells or tissues” in FDA’s interpretation of a “regenerative medicine therapy” that may be eligible for RMAT designation.

Read more

David Horowitz

David Horowitz,

Washington, D.C.

Michael N. Druckman

Michael N. Druckman,

Washington, D.C.

David M. Fox

David M. Fox,

Washington, D.C.

Susan S. Lee

Susan S. Lee,

Washington, D.C.

Loading data